Experienced CEO moves to Umeå life science company
Umeå-based life science company Inficure Bio has appointed Lena Söderström, who was previously in charge at stock exchange listed company Senzime, as its new chairman of the board of directors.
News
We are looking for consultants to an advisory board
Do you have a large network and want to help companies in Västerbotten to find the right competence? Then you are welcome to join our advisory board.
New article about great discovery – written by UBI company
Two representatives of the UBI company Mucocort have published an article in the Stockholm Intellectual Property Law Review on one of the most interesting research discoveries the recent decades – the discovery of CRISPR/Cas9, which can result in a Nobel Prize.
It’s a fact – the perfect entrepreneur doesn’t exist!
A new report has busted many of the myths surrounding super entrepreneurs, claiming they do not generally have higher IQs than the average person and are not necessarily driven by revenge following a troubled childhood.
The report, compiled by the Stockholm-based Sting incubator together with Umeå Biotech Incubator and researchers from Karolinska Institutet also discovered several important abilities that characterise successful entrepreneurs.
Swedish life science company awarded millions to develop cure for tooth loss
Swedish life science company Omnio has received millions in funding from the Swelife innovation programme to help develop a cure for tooth loss.
“Thanks to these funds from Swelife we can now move forward even faster”, says Omnio’s CEO Patric Stafshede.
Olympic biathlete appointed new CEO of Life Science company
Former Olympic biathlete Anders Mannelqvist has been appointed the new CEO of Pro Test Diagnostics, a Life Science company that has developed a unique test kit for blood doping.
Life science profile swaps stock market for startup
Life science industry figurehead Pernilla Abrahamsson has left her position as Product Development Manager at stock market listed Senzime to become Chief Operating Officer (COO) at Lipum, located at the Umeå Biotech Incubator.
Efficiency record at seminar
Together with Innovation Plus, we arranged a seminar on product development April 25th, going from prototype to large-scale manufacturing and clinical trials for pharmaceuticals, medical technology and diagnostics.
Life science company wins biggest order in its history
Umeå-based life science company Inficure Bio has just won the largest contract in its history.
“It feels incredible! The more large customers we get the greater our credibility becomes. This agreement is a real feather in our cap”, says Sofia Mayans, CEO of Inficure Bio.
Umeå life science company attends world congress – “Our product has huge potential”
Umeå life science company Lipum will participate in one of the world’s largest congresses for rheumatic diseases this June.
“The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, CEO of Lipum.
Lipum secures SEK 25 million in new share issue
Umeå-based Lipum, which is developing a biological drug for the treatment of chronic inflammation, has attracted SEK 25 million in new investment to help boost the company’s growth.
Jennie Ekbeck: Therefore, UBI is a rebel
How is it that so much happens in life science in Umeå? And why does Umeå Biotech Incubator call itself a rebel? UBI:s CEO Jennie Ekbeck answer this and more questions in an interview in Nordic Life science insight.
Umeå life science company granted millions to develop new product
Life science company Inficure Bio has been awarded millions by Vinnova to support the company’s development of a model that will help create new treatments for fibrosis.
“This money is incredibly important to us. Thanks to this investment we can now finish developing a new product”, says Sofia Mayans, CEO of Inficure Bio.
Life science companies in northern Sweden could double in a decade
Small and medium-sized life science companies operating in the Västerbotten county in Sweden will double in numbers over the next ten years, while a vibrant scientific community will add to the growth. These are the goals set by Umeå Biotech Incubator (UBI), which is now entering a new development phase of its incubator operation in Umeå.
North Sweden life science attracts interest at Bio Europe Spring in Vienna
BioEurope Spring in Vienna with 2 486 delegates, ranging from International investors to major companies. Our business coach Helén is in Vienna representing UBI and life science in northern Sweden.
Biotech Umeå Investment Day: Investors partner with 12 Västerbotten startups
For the eleventh year in a row Umeå Biotech Incubator hosted the Biotech Umeå Investment Day (BUID) (last Thursday) at Stockholm’s Grand Hôtel, when investors from Sweden and abroad got the opportunity to meet 12 companies from Västerbotten.
Kommunikationsansvarig från UBI börjar forska på cancerprevention
UBI:s kommunikationsansvariga, Carolina Hawranek, kommer under våren lämna sin postition för att istället att forska på heltid. Vi frågar lite om hennes tid på här UBI och om flytten till Umeå.
Researchers from Quretech Bio AB awarded additional funding of just over SEK 17 million
Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7.5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2.1 million from Umeå University).
From startup to super company with 115 percent growth
Recently, Uman Diagnostics received national attention after making it onto the list of “Sweden’s Super Companies 2018”. Niklas Norgren explains how an idea in the lab at Umeå University grew into a company and a success story.
Cancer-startup Hiloprobe partner up with team of investors and angels
Hiloprobe AB has signed off on a partnership deal with a group of public and private stakeholders who have come together to back this high-potential startup. Hiloprobe is now complemented with much needed business expertise – as Mattias Pettersson from Northern Light Capital joins the board of directors, The company aims to launch their product for improved colorectal cancer diagnosis by 2020.